CHRNA4 and schizophrenia: Agonists and positive allosteric modulators (PAMs) of the α7 nicotinic acetylcholine receptor (nAChR) are currently being developed to ameliorate cognitive deficits in diseases such as schizophrenia, ADHD and Alzheimer's disease [1], [2].